These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1913066)

  • 1. Neuro-endocrine cells--a new prognostic parameter in prostate cancer.
    Cohen RJ; Glezerson G; Haffejee Z
    Br J Urol; 1991 Sep; 68(3):258-62. PubMed ID: 1913066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostatic carcinoma: histological and immunohistological factors affecting prognosis.
    Cohen RJ; Glezerson G; Haffejee Z; Afrika D
    Br J Urol; 1990 Oct; 66(4):405-10. PubMed ID: 2224434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells.
    Bonkhoff H; Stein U; Remberger K
    Hum Pathol; 1995 Feb; 26(2):167-70. PubMed ID: 7532147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects.
    di Sant'Agnese PA
    Urology; 1998 May; 51(5A Suppl):121-4. PubMed ID: 9610566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?
    Allen FJ; Van Velden DJ; Heyns CF
    Br J Urol; 1995 Jun; 75(6):751-4. PubMed ID: 7613832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of neuroendocrine differentiation in prostate cancer.
    Ather MH; Abbas F
    Eur Urol; 2000 Nov; 38(5):535-42. PubMed ID: 11096233
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.
    Abrahamsson PA; Cockett AT; di Sant'Agnese PA
    Prostate Suppl; 1998; 8():37-42. PubMed ID: 9690662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma.
    Aprikian AG; Cordon-Cardo C; Fair WR; Zhang ZF; Bazinet M; Hamdy SM; Reuter VE
    J Urol; 1994 Apr; 151(4):914-9. PubMed ID: 8126824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
    Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
    Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors in prostate cancer].
    Bonkhoff H
    Pathologe; 2005 Nov; 26(6):433-43. PubMed ID: 16205900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy.
    Krijnen JL; Bogdanowicz JF; Seldenrijk CA; Mulder PG; van der Kwast TH
    J Urol; 1997 Jul; 158(1):171-4. PubMed ID: 9186347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging.
    Gleason DF; Mellinger GT;
    J Urol; 2017 Feb; 197(2S):S134-S139. PubMed ID: 28012760
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuroendocrine differentiation in stage D2 prostate cancers.
    Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
    Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostatic adenocarcinoma with marked neuroendocrine differentiation.
    Islam AM; Kato H; Hayama M; Kobayashi S; Ota H; Nishizawa O
    Int J Urol; 2001 Jul; 8(7):412-5. PubMed ID: 11442667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostatic adenocarcinoma with neuroendocrine differentiation of the small cell type].
    Rimoldi DA; Antonio Costa J; Roveto S; Rivero O
    Medicina (B Aires); 2001; 61(3):322-4. PubMed ID: 11474882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuroendocrine cancers of the prostate].
    Lépinard V; Dauge-Geffroy MC; Delmas V; Bertrand G; Fondimare A; Fetissof F
    Prog Urol; 1993 Feb; 3(1):86-94. PubMed ID: 8485600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
    Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
    J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine differentiation in prostate cancer.
    Shariff AH; Ather MH
    Urology; 2006 Jul; 68(1):2-8. PubMed ID: 16844446
    [No Abstract]   [Full Text] [Related]  

  • 20. The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms.
    Volante M; Rindi G; Papotti M
    Virchows Arch; 2006 Nov; 449(5):499-506. PubMed ID: 17033797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.